Chemistry:BK-5-MAPB

From HandWiki

βk-5-MAPB, or BK-5-MAPB, is an entactogen of the benzofuran and cathinone groups which is related to both 5-MAPB and methylone. It was patented by Matthew Baggott and Tactogen and is under investigation by Tactogen for potential medical use.[1][2][3][4]

Pharmacology

βk-5-MAPB acts as a monoamine releaser with selectivity for serotonin and has a similar potency to MDMA.[1][2][5][3][6] In terms of monoamine release, (S)-βk-5-MAPB has shown a DAT/SERT ratio of 0.6 and a DAT/NET ratio of 2.7, while (R)-βk-5-MAPB has shown a DAT/SERT ratio of 18 and a DAT/NET ratio of 1.9.[3] In addition, βk-5-MAPB, unlike MDMA, is a potent serotonin 5-HT1B receptor agonist.[7]

In rodent drug discrimination tests, (S)-βk-5-MAPB fully substitutes for MDMA whereas (R)-βk-5-MAPB partially substitutes for MDMA and dextroamphetamine at different doses, (R)-βk-5-MAPB and (S)-βk-5-MAPB both generalize to dextroamphetamine, and (S)-βk-5-MAPB but not (R)-βk-5-MAPB substitutes for DOM.[4] Hence, (S)-βk-5-MAPB shows entactogen-, psychedelic-, and stimulant-like effects, whereas (R)-βk-5-MAPB shows more stimulant-like effects, some entactogen-like effects, and no psychedelic-like effects.[4] In other tests, both (S)-βk-5-MAPB and (R)-βk-5-MAPB showed stimulant-like pro-impulsive effects, but (S)-βk-5-MAPB was more potent than (R)-βk-5-MAPB.[8]

See also

References

  1. ↑ 1.0 1.1 Baggott M, "Advantageous benzofuran compositions for mental disorders or enhancement", WO patent 2021/252538, published 16 December 2021
  2. ↑ 2.0 2.1 Baggott MJ, Lofthus SJ, De Leona XM, Singh A, Hudgins CJ, "Benzofuran salt morphic forms and mixtures for the treatment of mental disorders or mental enhancement", WO patent 2023/107653, published 21 September 2023
  3. ↑ 3.0 3.1 3.2 "Behavioral Assessments and Neurochemical Assays Differentiate the Effects of 1-(1-Benzofuran-5-yl)-2-(methylamino) propan-1-one Hydrochloride (BK-5-MAPB) Enantiomers". June 17-21, 2023: 85th CPDD Scientific Meeting, Denver, CO. June 2023. https://cpdd.org/wp-content/uploads/2023/07/Oral_Communications_Abstract_Book_Final.pdf#page=27. "Results: S-BK-5-MAPB produced dose-dependent increases in MDMA-lever responses and full substitution at 0.64 and 1.27 mg/kg; R-BK-5-MAPB produced less than 30% MDMA-lever responding. Both enantiomers increased distance traveled in a dose-dependent manner that was statistically significant compared to saline-treated controls (P= 0.0001). Both enantiomers were substrate-type releasers at all three transporters. The S-enantiomer displayed an MDMA-like profile with greater potency at SERT than DAT (DAT/SERT ratio of 0.6), while R-BK-5-MAPB had a typical stimulant profile (DAT/SERT ratio of 18). Both enantiomers had higher potency at DAT than NET (DAT/NET ratios of 2.7 and 1.9 for the S- and R-enantiomer, respectively). [...] Because they have reduced potency at NET, these novel substances may have utility in elucidating the contributions of NET to MDMA-like and typical stimulant effects." 
  4. ↑ 4.0 4.1 4.2 "Enantiomers of a novel benzofuran have distinct discriminative stimulus effects (Poster 18)". 16th Annual Behavior, Biology, and Chemistry (BBC): Translational Research in Substance Use Disorders, San Antonio, Texas, Embassy Landmark, 22-24 March 2024. March 2024. https://ww2.uthscsa.edu/ARTT/BBC/print/2024Program.pdf#page=20. 
  5. ↑ Baggott M, Dalziel S, "Specialized combinations for mental disorders or mental enhancement", WO patent 2023/107715, published 15 June 2023
  6. ↑ "Behavioral Assessments and Neurochemical Assays Differentiate the Effects of 1-(1-Benzofuran-5-yl)-2-(methylamino) propan-1-one Hydrochloride (BK-5-MAPB) Enantiomers". Drug and Alcohol Dependence 260. 2024. doi:10.1016/j.drugalcdep.2023.110018. 
  7. ↑ Matthew Baggott, "Advantageous benzofuran compositions for mental disorders or enhancement", US patent 20230150963, published 2023 May 18, assigned to Tactogen
  8. ↑ "Proimpulsive effects of acute treatment with 1-(1-benzofuran-5-yl)-2-(methylamino) propan1-one hydrochloride (BK-5-MAPB) enantiomers in rats (Poster 86)". 16th Annual Behavior, Biology, and Chemistry (BBC): Translational Research in Substance Use Disorders, San Antonio, Texas, Embassy Landmark, 22-24 March 2024. March 2024. https://ww2.uthscsa.edu/ARTT/BBC/print/2024Program.pdf#page=37. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:BK-5-MAPB&oldid=4178936"